SAMSUNG BIOLOGICS CO.,LTD.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureSamsung Biologics was established in 2011 and listed on the KOSPI in 2016 as a biopharmaceutical contract development and manufacturing organization (CDMO); in November 2025 it completed a spin-off creating Samsung Epis Holdings Co., Ltd. and transitioned to a structure focused on its CDMO business. Operating from Songdo, Incheon, the company provides contract manufacturing (CMO) of antibody biologics and contract development (CDO) services including cell line development and process development, supported by its proprietary cell line S-CHOice®, high-concentration formulation platforms S-Tensify™ and S-HiCon™, and antibody candidate selection platform DEVELOPICK™. Its five Songdo plants have combined production capacity of 785,000 liters, and in December 2025 it signed an agreement to acquire 100% of Human Genome Sciences Inc., which operates a 60,000-liter facility in Maryland, USA, while expanding into mRNA, ADC, and cell/gene therapy manufacturing and launching the 'Samsung Organoid' research services brand in June 2025.
Products & technology
- S-CHOice®Proprietary cell line for CDO services
- S-Tensify™High-concentration formulation platform
- DEVELOPICK™Antibody candidate selection platform
- S-HiCon™High-concentration formulation technology
- Samsung OrganoidResearch service for early efficacy evaluation of drug candidates
Companies in the same categoryPharma & CDMO
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Founded and listed on KOSDAQ in 2015, Kolmar BioTech is a nonclinical CRO providing efficacy testing for anticancer and metabolic disease drug candidates.
Founded in 2007, SK Innovation is an energy company spanning oil, chemicals, batteries, and LNG, merged with SK E&S in 2024.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition